Table 2.
Comparison of other genetic alterations between AML patients in low and high BDH2 expression groups
| Variant |
Number of patients with the gene alternation (percentage) |
P | ||
|---|---|---|---|---|
| Whole cohort | Low BDH2, expression | High BDH2, expression | ||
|
NPM1mut |
36 (31.85%) |
16 (28.07%) |
20 (35.71%) |
0.271 |
|
FLT3-ITD |
23 (20.35%) |
7 (12.28%) |
16 (28.57%) |
0.030* |
|
FLT3-TKD |
8 (7.08%) |
5 (8.77%) |
3 (5.36%) |
0.338 |
|
NPM1mut/FLT3-ITDneg |
20 (17.70%) |
11(19.30%) |
9 (16.07%) |
0.368 |
|
CEBPAa |
34 (30.09%) |
16 (28.07%) |
18 (32.14%) |
0.444 |
|
CEBPADouble mutation |
9 (7.96%) |
3 (5.26%) |
6 (10.71%) |
0.593 |
|
IDH1b |
3 (3.75 %) |
1 (2.56 %) |
2 (4.88%) |
0.592 |
|
IDH2b |
8 (10 %) |
3 (7.69%) |
5 (12.20%) |
0.508 |
|
DNMT3Ab |
12 (15 %) |
10 (25.641%) |
2 (4.88%) |
0.009* |
|
MLLb |
7 (8.75%) |
3 (7.69%) |
4 (9.76%) |
0.426 |
|
ERGc |
11.17 (10.26-12.08) |
11.60 (10.48-12.72) |
10.68 (9.17-12.20) |
0.320 |
|
MN1c |
12.98 (12.28-13.68) |
13.35 (12.42-14.28) |
12.55 (11.47-13.64) |
0.257 |
|
miR-181ac |
3.12 (2.57-3.67) |
3.17 (2.35-3.98) |
3.07 (2.30-3.84) |
0.864 |
| miR-3151c | 12.35 (11.90-12.80) | 12.18 (11.53-12.84) | 12.53 (11.89-13.16) | 0.448 |
Values are number (%) of patients with alteration.
aCEBPAsingle and double mutations.
bOnly 80 patients with high quality of DNA to sequence; 39 patients are low BDH2 expression and 41 patients are high expression.
cMean (95% CI).
*Statistically significant (P < 0.05).